HER2-PET imaging to predict response to T-DXd in advanced breast cancer
Part of Cancer clinical trials.
This study is testing whether a special PET scan (HER2-PET) can help predict how well the drug T-DXd (also known as Enhertu) might work for your breast cancer. T-DXd is a targeted therapy that delivers chemotherapy directly to cancer cells with certain markers. The trial will check if the scan can identify which patients are more likely to benefit, which could help personalize treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have advanced breast cancer that can't be removed with surgery, or cancer that has spread to other parts of the body.
- Your cancer must be HER2-positive or HER2-low, as determined by a previous biopsy.
- If your cancer is HR-positive (uses hormones to grow) and HER2-negative, you must have already used a CDK4/6 inhibitor (like palbociclib) and the cancer continued to grow.
- You have a small number of brain or lymph node lesions that responded completely to the previous radiation therapy, and your cancer has not progressed for at least 4 weeks since the last fraction of irradiation.
- You are not pregnant, and you and your partner are using reliable contraception.
- You are willing to undergo the PET scan and receive study treatment according to protocol.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new drug called HER3-DXd (alone or combined with other medicines) for people with advanced breast cancer that has already been treated with T-DXd (Enhertu) and then got worse. The goal is to see if the new drug can shrink tumors safely.
This trial uses a blood test to look for tumor DNA in women with a certain type of advanced breast cancer (HR-positive, HER2-low). If the DNA doesn't disappear after starting standard hormone therapy with a CDK4/6 inhibitor, participants may be switched to a targeted drug called T-DXd (trastuzumab deruxtecan).
This study tests whether a special imaging scan can help doctors see how well breast cancer responds to a drug called T-DXd. You will get the imaging agent before your usual T-DXd treatment, and the scan will show if the drug is reaching the tumors.
This study tests a drug called T-DXd (trastuzumab deruxtecan) for people with advanced breast cancer that has very low levels of HER2 (a protein that helps cancer grow) and that is also hormone receptor positive. The goal is to see if this drug can help shrink or slow the cancer.
This study looks at how well the drug T-DXd (Enhertu) works against breast cancer that has spread or can't be removed with surgery. It includes patients with any level of HER2 protein, so it might be an option even if your cancer has low HER2.
This study looks at how well a drug called trastuzumab deruxtecan works in people with HER2-low breast cancer that has spread to other parts of the body. It uses PET-CT scans to check the tumor's response to treatment.
Hear when a new Breast Cancer Metastatic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.